{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:53:56Z","timestamp":1788220436281,"version":"build-2803163510"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF17SA0027784"],"award-info":[{"award-number":["NNF17SA0027784"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recent European Union (EU) initiatives and legislation have considerably increased public access to clinical trials data (CTD). These developments are generally much welcomed for the enhancement of science, trust, and open innovation. However, they also raise many questions and concerns, not least at the interface between CTD transparency and other areas of evolving EU law on the protection of trade secrets, IPRs, and privacy. This article focuses on privacy issues and on the interrelation between developments in transparency and the EU\u2019s new General Data Protection Regulation 2016\/679 (GDPR). More specifically, this article examines: (1) the origins and rationales of EU transparency regulations, including the incidents and concerns that have shaped them; (2) the features and implications of the GDPR which are relevant in the context of clinical trials; and (3) the risk for tensions between the GDPR and the policy goals of CTD transparency, as well as implications for data sharing and open innovation. Ultimately, we elaborate on factors that should be carefully considered and addressed to reap the full benefits of CTD transparency.<\/jats:p>","DOI":"10.1093\/scipol\/scaa014","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T12:10:04Z","timestamp":1580472604000},"page":"616-626","source":"Crossref","is-referenced-by-count":26,"title":["Clinical trial data transparency and GDPR compliance: Implications for data sharing and open innovation"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-4888","authenticated-orcid":false,"given":"Timo","family":"Minssen","sequence":"first","affiliation":[{"name":"Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), University of Copenhagen (UCPH), Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9575-298X","authenticated-orcid":false,"given":"Neethu","family":"Rajam","sequence":"additional","affiliation":[{"name":"Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), University of Copenhagen (UCPH), Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Bogers","sequence":"additional","affiliation":[{"name":"Department of Food & Resource Economics (IFRO), University of Copenhagen (UCPH), Copenhagen, Denmark"},{"name":"Haas School of Business, University of California, Berkeley, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"2021042420402646500_scaa014-B1","author":"Baker","year":"2019"},{"issue":"5","key":"2021042420402646500_scaa014-B2","first-page":"479","article-title":"Open Source Drug Discovery: A New Paradigm of Collaborative Research in Tuberculosis Drug Development","volume":"91","author":"Bhardwaj","year":"2011","journal-title":"Tuberculosis"},{"issue":"1","key":"2021042420402646500_scaa014-B3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1108\/14601061111104715","article-title":"The Open Innovation Paradox: Knowledge Sharing and Protection in R&D Collaborations","volume":"14","author":"Bogers","year":"2011","journal-title":"European Journal of Innovation Management"},{"issue":"2","key":"2021042420402646500_scaa014-B4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0008125617745086","article-title":"Open Innovation: Research, Practices, and Policies","volume":"60","author":"Bogers","year":"2018","journal-title":"California Management Review"},{"key":"2021042420402646500_scaa014-B5","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMp1409464","article-title":"Transparency and the EMA-Sharing of Clinical Trial Data","volume":"371","author":"Bonini","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"2021042420402646500_scaa014-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/acprof:oso\/9780199682461.003.0001","volume-title":"New Frontiers in Open Innovation","author":"Chesbrough","year":"2014"},{"issue":"3","key":"2021042420402646500_scaa014-B7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/jama.2018.5630","article-title":"HIPAA and Protecting Health Information in the 21st Century","volume":"320","author":"Cohen","year":"2018","journal-title":"Journal of the American Medical Association"},{"issue":"12","key":"2021042420402646500_scaa014-B8","first-page":"1141","article-title":"\u2018Big Data, Big Tech, and Protecting Patient Privacy\u2019","volume":"322","author":"Cohen","year":"2019"},{"key":"2021042420402646500_scaa014-B10","author":"Confessore","year":"2018"},{"key":"2021042420402646500_scaa014-B11","author":"Dias","year":"2015"},{"key":"2021042420402646500_scaa014-B12","author":"Donovan","year":"2018"},{"key":"2021042420402646500_scaa014-B13","author":"El Emam","year":"2015"},{"key":"2021042420402646500_scaa014-B14","author":"Gogates","year":"2018"},{"key":"2021042420402646500_scaa014-B15","author":"Harford","year":"2018"},{"key":"2021042420402646500_scaa014-B9","author":"Hodson","year":"2018"},{"issue":"2","key":"2021042420402646500_scaa014-B16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.lrp.2017.08.007","article-title":"The Evolution of Intellectual Property Strategy in Innovation Ecosystems: Uncovering Complementary and Substitute Appropriability Regimes","volume":"51","author":"Holgersson","year":"2018","journal-title":"Long Range Planning"},{"issue":"13","key":"2021042420402646500_scaa014-B17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2016.14668","article-title":"\u2018Toward a New Era of Trust and Transparency in Clinical Trials\u2019","volume":"316","author":"Hudson","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"2021042420402646500_scaa014-B18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pst.1615","article-title":"Preparing Individual Patient Data from Clinical Trials for Sharing: The GlaxoSmithKline Approach","volume":"13","author":"Hughes","year":"2014","journal-title":"Pharmaceutical Statistics"},{"key":"2021042420402646500_scaa014-B500","volume-title":"Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk","year":"2015"},{"key":"2021042420402646500_scaa014-B19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ejhg.2014.71","article-title":"Dynamic Consent: A Patient Interface for Twenty-First Century Research Networks","volume":"23","author":"Kaye","year":"2015","journal-title":"European Journal of Human Genetics"},{"key":"2021042420402646500_scaa014-B20","doi-asserted-by":"crossref","first-page":"g2579","DOI":"10.1136\/bmj.g2579","article-title":"Transparency Campaigners Welcome New Rules for Clinical Trials in Europe","volume":"348","author":"Kmietowicz","year":"2014","journal-title":"BMJ"},{"key":"2021042420402646500_scaa014-B21","doi-asserted-by":"crossref","first-page":"e015110","DOI":"10.1136\/bmjopen-2016-015110","article-title":"Clinical Trial Transparency: A Reassessment of Industry Compliance with Clinical Trial Registration and Reporting Requirements in the United States","volume":"7","author":"Lassman","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"2021042420402646500_scaa014-B22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jlme.12012","article-title":"Pharmaceutical Knowledge Governance: A Human Rights Perspective","volume":"41","author":"Lemmens","year":"2013","journal-title":"Journal of Law Medicines and Ethics"},{"key":"2021042420402646500_scaa014-B24226250","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review","volume":"326","author":"Lexchin","year":"2003","journal-title":"British Medical Journal"},{"issue":"3","key":"2021042420402646500_scaa014-B23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1056\/NEJMe1516564","article-title":"Data Sharing","volume":"374","author":"Longo","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"2021042420402646500_scaa014-B24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.technovation.2011.11.004","article-title":"Innovation Risks of Outsourcing in Pharmaceutical New Product Development","volume":"32","author":"Lowman","year":"2012","journal-title":"Technovation"},{"issue":"3","key":"2021042420402646500_scaa014-B25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/scipol\/scv077","article-title":"Twenty Challenges for Innovation Studies","volume":"43","author":"Martin","year":"2016","journal-title":"Science and Public Policy"},{"key":"2021042420402646500_scaa014-B26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrd.2017.70","article-title":"How Much Do Clinical Trials Cost","volume":"16","author":"Martin","year":"2017","journal-title":"Nature Reviews Drug Discovery"},{"issue":"17","key":"2021042420402646500_scaa014-B27","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMhle1309073","article-title":"Preparing for Responsible Sharing of Clinical Trial Data","volume":"369","author":"Mello","year":"2013","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"2021042420402646500_scaa014-B28","first-page":"43","article-title":"Clinical Trial Transparency: Many Gains But Access to Evidence for New Medicines Remains Imperfect","volume":"116","author":"Mintzes","year":"2015","journal-title":"British Medical Bulletin"},{"key":"2021042420402646500_scaa014-B29","author":"Minssen","year":"2019"},{"issue":"4","key":"2021042420402646500_scaa014-B30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.trci.2017.10.005","article-title":"Drug Discovery and Development: Role of Basic Biological Research","volume":"3","author":"Mohs","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2021042420402646500_scaa014-B31","author":"Monteleone","year":"2017"},{"issue":"7","key":"2021042420402646500_scaa014-B32","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/ejhg.2015.239","article-title":"Big Data in Medical Research and EU Data Protection Law: Challenges to the Consent or Anonymise Approach","volume":"24","author":"Mostert","year":"2016","journal-title":"European Journal of Human Genetics"},{"key":"2021042420402646500_scaa014-B33","doi-asserted-by":"crossref","first-page":"k510","DOI":"10.1136\/bmj.k510","article-title":"Data Sharing in Medical Research","volume":"360","author":"Packer","year":"2018","journal-title":"BMJ"},{"key":"2021042420402646500_scaa014-B34","year":"2015"},{"key":"2021042420402646500_scaa014-B35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nbt.3243","article-title":"Will Clinical Trial Data Disclosure Reduce Incentives to Develop New Uses of Drugs","volume":"33","author":"Price","year":"2015","journal-title":"Nature Biotechnology"},{"issue":"6426","key":"2021042420402646500_scaa014-B36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.aav5133","article-title":"Shadow Health Records Meet New Data Privacy Laws: How Will Research Respond to a Changing Regulatory Space","volume":"363","author":"Price","year":"2019","journal-title":"Science"},{"key":"2021042420402646500_scaa014-B37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41591-018-0272-7","article-title":"Privacy in the Age of Medical Big Data","volume":"25","author":"Price","year":"2019","journal-title":"Nature Medicine"},{"issue":"3","key":"2021042420402646500_scaa014-B38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ddr.21526","article-title":"What Lurks in the Shadows of the Openness Hyperbole for Biopharmaceuticals","volume":"80","author":"Rajam","year":"2019","journal-title":"Drug Development Research"},{"key":"2021042420402646500_scaa014-B39","author":"Robins","year":"2019"},{"issue":"2","key":"2021042420402646500_scaa014-B40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCOUTCOMES.112.965798","article-title":"The Importance of Clinical Trial Data Sharing: Toward More Open Science","volume":"5","author":"Ross","year":"2012","journal-title":"Circulation, Cardiovascular Quality and Outcomes"},{"issue":"1","key":"2021042420402646500_scaa014-B41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12967-016-0838-4","article-title":"Changing R&D Models in Research-Based Pharmaceutical Companies","volume":"14","author":"Schuhmacher","year":"2016","journal-title":"Journal of Translational Medicine"},{"key":"2021042420402646500_scaa014-B42","author":"Siwicki","year":"2018"},{"key":"2021042420402646500_scaa014-B43","year":"2019"},{"issue":"6","key":"2021042420402646500_scaa014-B44","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jamia\/ocv077","article-title":"Big Biomedical Data as the Key Resource for Discovery Science","volume":"22","author":"Toga","year":"2015","journal-title":"Journal of the American Medical Informatics Association"},{"key":"2021042420402646500_scaa014-B45","author":"Toth","year":"2018"},{"key":"2021042420402646500_scaa014-B46","author":"Travis","year":"2011"},{"key":"2021042420402646500_scaa014-B47","article-title":"Protecting Patient Privacy When Sharing Patient-Level Data from Clinical Trials","volume":"16, 77","author":"Tucker","year":"2016","journal-title":"BMC Medical Research Methodology"},{"key":"2021042420402646500_scaa014-B48","author":"Van Der Marel","year":"2014"},{"key":"2021042420402646500_scaa014-B49","first-page":"g4073","article-title":"European Medicines Agency Changes Policy on Clinical Trial Data Publication","volume":"4073","author":"Watson","year":"2014","journal-title":"BMJ Clinical Research"},{"key":"2021042420402646500_scaa014-B50","doi-asserted-by":"crossref","first-page":"160018","DOI":"10.1038\/sdata.2016.18","article-title":"\u2018The FAIR Guiding Principles for Scientific Data Management and Stewardship\u2019,","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Scientific Data"}],"container-title":["Science and Public Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/spp\/article-pdf\/47\/5\/616\/37337385\/scaa014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/spp\/article-pdf\/47\/5\/616\/37337385\/scaa014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T20:41:33Z","timestamp":1619296893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/spp\/article\/47\/5\/616\/5780440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3,4]]},"published-print":{"date-parts":[[2021,4,24]]}},"URL":"https:\/\/doi.org\/10.1093\/scipol\/scaa014","relation":{},"ISSN":["0302-3427","1471-5430"],"issn-type":[{"value":"0302-3427","type":"print"},{"value":"1471-5430","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,3,4]]}}}